In an attempt to identify the most suitable HDAC target in leukemias and lymphomas, Matthews et al. identified that HDAC3 knockdown resulted in decreased lymphoma cell proliferation and a reduced tumor mass in mouse xenografts [186]. This evidence concerns the gene HDAC3 and lymphoma.